ReviewThe British journal of ophthalmology2015
Myopic choroidal neovascularisation: current concepts and update on clinical management.
Review in The British journal of ophthalmology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 4 syntheses or guidelines pooled it, 153 citations in OpenAlex.
- Acute Kidney Injury from Intravitreal Anti-vascular Endothelial Growth Factor Drugs: A Systematic Review and Meta-analysis of Randomized Controlled Trials.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023Pooled it
- Recurrence risk of myopic choroidal neovascularisation: a systematic review of current study.BMJ open ophthalmology · 2023Pooled it
- Pooled it
- A systematic review of clinical practice guidelines for myopic macular degeneration.Journal of global health · 2022Pooled it
- Perforating scleral vessel angular metrics as a structural biomarker of myopic choroidal neovascularisation.Eye (London, England) · 2026Article
- Ten-year outcomes of intravitreal injection of ranibizumab for the treatment of myopic choroidal neovascularization.Medicine · 2026Article
- The Antiangiogenic Effect of VEGF-A siRNA-FAM-Loaded Exosomes.Bioengineering (Basel, Switzerland) · 2025Article
- Article
- Clinical and Socioeconomic Burden of Retinal Diseases: Can Biosimilars Add Value? A Narrative Review.Ophthalmology and therapy · 2025Review
- Efficacy and safety of intravitreal anti-VEGF for myopic choroidal neovascularization.International journal of ophthalmology · 2025Article
- 'Structural OCT changes distinguishing between myopic macular haemorrhages due to choroidal neovascularization and spontaneous Bruch's membrane rupture: the "myopic 2 binary reflective sign".Eye (London, England) · 2024Article
- Characterizing Macular Neovascularization in Myopic Macular Degeneration and Age-Related Macular Degeneration Using Swept Source OCTA.Clinical ophthalmology (Auckland, N.Z.) · 2023Article
- Association between peripheral visual field defects and focal lamina cribrosa defects in highly myopic eyes.Japanese journal of ophthalmology · 2022Article
- Baseline predictors for good visual gains after anti-vascular endothelial growth factor therapy for myopic choroidal neovascularization.Scientific reports · 2022Article
- Risk factors for myopic choroidal neovascularization-related macular atrophy after anti-VEGF treatment.PloS one · 2022Article
- Incidence, predictors and re-treatment outcomes of recurrent myopic choroidal neo-vascularization.PloS one · 2022Article
- Predicting Optical Coherence Tomography-Derived High Myopia Grades From Fundus Photographs Using Deep Learning.Frontiers in medicine · 2022Article
- Genetic Polymorphisms Affecting Ranibizumab Response in High Myopia Patients.Pharmaceutics · 2021Article
- Association between choriocapillaris flow deficit and choroidal neovascularization activity in eyes with myopic choroidal neovascularization.Scientific reports · 2021Observational
- A Three-Dimensional-reconstruction-based study on the ocular volume of Chinese children with high myopia.BMC ophthalmology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 9 institutions in 9 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Choroidal neovascularisation (CNV) is a common vision-threatening complication of myopia and pathological myopia. Despite significant advances in understanding the epidemiology, pathogenesis and natural history of myopic CNV, there is no standard definition of myopic CNV and its relationship to axial length and other myopic degenerative changes. Several treatments are available to ophthalmologists, but with the advent of new therapies there is a need for further consensus and clinical management recommendations. Verteporfin photodynamic therapy has been an established treatment for subfoveal myopic CNV for many years, but this treatment does not restore visual acuity and is associated with long-term chorioretinal atrophy. More recently, clinical trials investigating the efficacy and safety of anti-vascular endothelial growth factor agents in patients with myopic CNV have demonstrated substantial visual acuity gains and quality of life increases compared with photodynamic therapy. These enhanced outcomes provide updated evidence-based clinical management guidelines of myopic CNV, and increase the need for a generally accepted definition for myopic CNV. This review critically summarises the latest myopic CNV literature in the context of clinical experience and recommends a myopic CNV treatment algorithm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.